Pipeline
Meet our molecules

Pipeline

We are currently engaged in 2 fully owned and 4 co-development programs progressing from hit id to preclinical stage using BIOPTIC Scientific AI.

Product
Therapeutic area
Start date
Hit Identification
Hit-to-Lead
Lead Optimization
Pre-clinical
Product
Therapeutic area
Start date
Hit ID
Hit-to-Lead
Lead Opt
Pre-Clinical
OPT-LR42
fully owned
Neurodegenerative
Parkinson LRRK2
Start date
May, 2024
Hit ID
Hit-to-Lead
Lead Opt
Pre Clinical
Lead optimization
OPT-TN65
fully owned
Metabolic
Obesity TNIK
Start date
June, 2024
Hit ID
Hit-to-Lead
Lead Opt
Pre Clinical
Lead optimization
OPT-FL95
co-owned
Oncology
Solid tumors VEGFR3
Start date
November, 2024
Hit ID
Hit-to-Lead
Lead Opt
Pre Clinical
Hit-to-lead
OPT-M501
partner program
Neurodegenerative
undisclosed
Start date
July, 2024
Hit ID
Hit-to-Lead
Lead Opt
Pre Clinical
Hit-to-lead
OPT-C216
partner porogram
Oncology
undisclosed
Start date
March, 2024
Hit ID
Hit-to-Lead
Lead Opt
Pre Clinical
Hit-to-lead
OPT-G322
partner porogram
Autoimmune
undisclosed
Start date
May 2025
Hit ID
Hit-to-Lead
Lead Opt
Pre Clinical
Hit ID